Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses

Blood

Volumn 94, Issue 3, 1999, Pages 902-908

  Rook, Alain H ^a   Wood, Gary S ^b   Yoo, Elisa K ^b   Elenitsas, Rosalie ^b   Kao, David M F ^b   Sherman, Matthew L ^b   Witmer, William K ^b   Rockwell, Kenneth A ^b   Shane, Ryan B ^b   Lessin, Stuart R ^b   Vonderheid, Eric C ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 12;

ADULT; AGED; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEZARY SYNDROME; SUBCUTANEOUS DRUG ADMINISTRATION; T CELL LYMPHOMA; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; TUMOR REGRESSION;

EID: 0033178680     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.3.902.415k23_902_908     Document Type: Article

References (28)

1. Diamandidou E, Cohen PR, Kurzrock R: Mycosis fungoides and Sezary syndrome. Blood 88:2385, 1996
2. Weiss LM, Wood GS, Hu E, Abel EA, Hoppe RT, Sklar J: Detection of clonal T-cell receptor gene rearrangements in the peripheral blood of patients with mycosis fungoides/Sezary syndrome. J Invest Dermatol 92:601, 1989
3. Hoppe RT, Wood GS, Abel EA: Mycosis fungoides and the Sezary syndrome: Pathology, staging and treatment. Curr Probl Cancer 14:293, 1990
4. Rook AH, Yoo EK, Grossman DJ, Kao DMF, Fox FE, Niu Z: Use of biological response modifiers in the treatment of cutaneous T-cell lymphoma. Curr Opin Oncology 10:170, 1998
5. 382 IL-2 fusion toxin in cutaneous T-cell lymphoma. J Am Acad Dermatol 39:63, 1998
6. Marolleau JP, Baccard M, Flageul B, Rybojad M, Laroche L, Verola O, Brandely M, Morel P, Gisselbrecht C: High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. Arch Dermatol 131:574, 1995
7. Rook AH, Lessin SR, Jaworsky C, Singh A, Vowels BR: Immunopathogenesis of cutaneous T-cell lymphoma. Abnormal cytokine production by Sezary T-cells. Arch Dermatol 129:486, 1993
8. Wood NL, Kitces EN, Blaylock WK: Depressed lymphokine activated killer cell activity in mycosis fungoides. Arch Dermatol 126:907, 1990
9. Vowels BR, Cassin M, Vonderheid E, Rook AH: Aberrant cytokine production by Sezary syndrome patients. Cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 99:90, 1992
10. Dummer R, Heald PW, Nestle FO, Ludwig E, Laine E, Hemmi S, Burg G: Sezary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain). Blood 88:1383, 1996
11. Asadullah K, Docke WD, Haeussler A, Sterry W, Volk HD: Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10. J Invest Dermatol 107:833, 1996
12. Trinchieri G: Interleukin-12: A cytokine at the interface of inflammation and immunity. Adv Immunol 70:83, 1998
13. Chan SH, Perussia B, Gupta JW, Kobayashi M, Pospisil M, Young HA, Wolf SF, Young D, Clark SC, Trinichieri G: Induction of IFN γ production by NK cell stimulatory factor (NKSF): Characterization of the responder cells and synergy with other inducers. J Exp Med 173:869, 1991
14. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B, Trinchieri G: Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 170:827, 1989
15. Chouaib S, Chehimi J, Bani L, Genetet N, Tursz T, Gay F, Trinchieri G, Mami-Chouaib F: Interleukin-12 induces the differentiation of major histocompatibility complex class I-primed cytotoxic T-lymphocyte precursors into allospecific cytotoxic effectors. Proc Natl Acad Sci USA 91:12659, 1994
16. Rook AH, Kubin M, Cassin M, Vonderheid EC, Vowels BR, Wolfe JT, Wolf S, Trinchieri G, Lessin SR: Interleukin 12 reverses cytokine and immune abnormalities in Sezary syndrome. J Immunol 154:1491, 1995
17. Hoppe RT, Medeiros LJ, Warnke RA, Wood GS: CDS+ tumor-infiltrating lymphocytes influence survival of patients with mycosis fungoides. J Am Acad Dermatol 32:448, 1995
18. Wood GS, Tung RM, Haeffner AC, Crooks CF, Liao S, Orozco R, Veelken H, Kadin ME, Koh H, Heald P: Detection of clonal T-cell receptor γ gene rearrangements in early mycosis fungoides/Sezary syndrome by polymerase chain reaction and denaturing gradient gel electrophoresis (PCR/DGGE). J Invest Dermatol 103:34, 1994
19. Wood GS, Edinger A, Hoppe RT, Warnke RA: Mycosis fungoides skin lesions contain CD8 positive tumor infiltrating lymphocytes expressing an activated MHC restricted cytotoxic T-lymphocyte phenotype. J Cutan Pathol 21:151, 1994
20. Wolfe JT, Chooback L, Finn DT, Jaworsky C, Rook AH, Lessin SR: Large cell transformation following detection of minimal residual disease in cutaneous T-cell lymphoma: Molecular and in situ analysts of a single neoplastic T-cell clone expressing the identical T-cell receptor. J Clin Oncol 13:1751, 1995
21. Vonderheid EC, Ekbote SK, Kerrigan K, Kalmanson JD, Van Scott EJ, Rook AH, Abrams JT: The prognostic significance of delayed hypersensitivity to dinitrochlorobenzene and mechlorethamine hydrochloride in cutaneous T-cell lymphoma. J Invest Dermatol 110:946, 1998
22. Rook AH, Heald P: The immunopathogenesis of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 9:997, 1995
23. Peleman R, Wu J, Rargeas C, Delespesse G: Recombinant interleukin 4 suppresses the production of interferon gamma by human mononuclear cells. J Exp Med 170:1751, 1989
24. D'Andrea A, Aste-Amea M, Valiante NM, Ma X, Kubin M, Trinchieri G: Interleukin-10 inhibits human lymphocyte IFN-γ production by suppressing natural killer cell stimulatory factor/interleukin-12 synthesis in accessory cells. J Exp Med 178:1041, 1993
25. Showe L, Fox FE, Niu Z, Williams D, Rook AH: Depressed interleukin-12 mediated signal transduction in T-cells from patients with Sezary syndrome is associated with the absence of IL-12 receptor beta2 mRNA expression. J Invest Dermatol 112:602, 1999 (abstr)
26. Jacobson NG, Szabo SJ, Weber-Nordt RM, Zhong Z, Schreiber RD, Darnell JE Jr, Murphy KM: Interleukin-12 signaling in T helper type (Th1)1 cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat) 3 and Stat 4. J Exp Med 181:1755, 1995
27. Rogge L, Barberis-Maino L, Biffi M, Passini N, Presky DH, Gubler U, Sinigaglia F: Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J Exp Med 185:825, 1997
28. Cohen J: IL-12 deaths: Explanation and a puzzle. Science 270:908, 1995